186 related articles for article (PubMed ID: 12599559)
1. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
Nakashima J
Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
[No Abstract] [Full Text] [Related]
2. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers].
Yamamoto I; Morita R; Konishi J; Shigeno C; Ikekubo K; Hino M; Sone T; Fujimoto R
Kaku Igaku; 1995 May; 32(5):501-10. PubMed ID: 7596071
[TBL] [Abstract][Full Text] [Related]
3. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract][Full Text] [Related]
4. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
5. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
Nemoto S; Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
[No Abstract] [Full Text] [Related]
6. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
8. Pediatric reference intervals for four serum bone markers using two automated immunoassays.
Wyness SP; Roberts WL; Straseski JA
Clin Chim Acta; 2013 Jan; 415():169-72. PubMed ID: 23122966
[No Abstract] [Full Text] [Related]
9. Dissociation of bone formation markers in bone metastasis of prostate cancer.
Koizumi M; Maeda H; Yoshimura K; Yamauchi T; Kawai T; Ogata E
Br J Cancer; 1997; 75(11):1601-4. PubMed ID: 9184174
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy].
Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Nakada J
Kaku Igaku; 1999 May; 36(4):333-9. PubMed ID: 10390956
[TBL] [Abstract][Full Text] [Related]
11. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
12. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
13. [The usefulness of early whole body bone scintigraphy in the detection of bone metastasis from prostatic cancer].
Otsuka N; Fukunaga M; Furukawa Y; Tanaka H
Kaku Igaku; 1994 Jun; 31(6):541-50. PubMed ID: 7520953
[TBL] [Abstract][Full Text] [Related]
14. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours. Comparison with the results of 99mTc-methylene bisphosphonate bone scintigraphy.
Withold W; Georgescu G; Khakzad H; Vosberg H; Mueller-Gaertner HW; Reinauer H
Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):479-85. PubMed ID: 8547430
[TBL] [Abstract][Full Text] [Related]
16. A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases.
Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Murai M
Urol Int; 1997; 58(4):236-8. PubMed ID: 9253125
[TBL] [Abstract][Full Text] [Related]
17. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
18. Staging of prostatic carcinoma with radionuclide bone scintigraphy and lymphography.
Hayward SJ; McIvor J; Burdge AH; Jewkes RF; Williams G
Br J Radiol; 1987 Jan; 60(709):79-81. PubMed ID: 3814999
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
Kobayashi Y; Tokue A
Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
[TBL] [Abstract][Full Text] [Related]
20. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer?
Perachino M; Di Ciolo L; Barbetti V; Puppo P
Eur Urol; 1996; 29(3):366-9. PubMed ID: 8740025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
